Monica Michele Carrozzo McSherry: Converging Pathways Between Homocysteine and Cholesterol in Cardiovascular Risk
Monica Michele Carrozzo McSherry, Registered Nutritional Therapist at Healthmatters Health Store, Freelance Writer at Dulwich Nutrition, shared a post on LinkedIn:
“Homocysteine (Hcy), a sulfur-containing amino acid derived from methionine metabolism, is remethylated to methionine via folate and vitamin B12 or transsulfurated to cystathionine via vitamin B6.
Elevated plasma Hcy, or hyperhomocysteinemia, is a recognized risk factor for atherosclerosis, primarily through endothelial dysfunction, oxidative stress, and inflammation.
Hcy promotes reactive oxygen species formation, reduces nitric oxide bioavailability, and stimulates pro-inflammatory pathways, accelerating vascular injury.
Cholesterol, particularly LDL-C, drives atherogenesis through subendothelial deposition, oxidation, and foam cell formation, whereas HDL-C facilitates reverse cholesterol transport and vascular protection.
Evidence indicates that hyperhomocysteinemia interacts with lipid metabolism by increasing LDL oxidation, impairing HDL function, and modulating hepatic cholesterol synthesis.
Oxidized LDL generated under elevated Hcy conditions is highly atherogenic, while inhibition of HDL-associated paraoxonase-1 reduces antioxidant defense, compounding vascular risk.
Genetic variants affecting homocysteine metabolism, such as MTHFR C677T, associate with elevated Hcy and altered lipid profiles, highlighting a combined genetic predisposition to cardiovascular disease.
Epidemiological data suggest additive risk when hyperhomocysteinemia coexists with dyslipidemia.
While B-vitamin supplementation lowers Hcy levels, effects on lipid profiles and cardiovascular outcomes are inconsistent, reflecting complex interactions involving oxidative stress, endothelial repair, and lipid oxidation.
In summary, homocysteine and cholesterol are intertwined modulators of cardiovascular risk.
Hyperhomocysteinemia exacerbates LDL oxidation and HDL dysfunction, potentiating atherogenesis.
Beyond lipid-lowering therapies, nutritional strategies targeting Hcy through folate, B12, and B6 may provide complementary cardiovascular protection, particularly in genetically susceptible populations.
Future research should clarify the mechanistic crosstalk and therapeutic implications of the homocysteine-cholesterol axis.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 04:06Allison Lewin: How Gender Shapes the Way We Receive Medical Care
-
Sep 21, 2026, 03:49Jessica Lee: Walking Together for a Stronger Bleeding Disorders Community
-
Sep 21, 2026, 03:36Syed Asif Ali Shah: From Pakistan to Australia – A Clinical Haematology Milestone
-
Sep 21, 2026, 03:22Katie Baca-Motes: Estradiol Fluctuations May Help Explain Menstrual Migraine
-
Sep 21, 2026, 03:00Family History Can Reveal Hidden Risk of Aortic Dissection – The Marfan Foundation
-
Sep 21, 2026, 02:47Transitioning from Paediatric to Adult Haemophilia Care – Haemophilia Foundation Australia
-
Sep 21, 2026, 02:29Diana Castro Paupério: A New Era for Patient Blood Management
-
Sep 21, 2026, 00:29Iheanyichukwu Ike: Childhood Anaemia in Nigeria Through an Analysis of the 2018 NDHS
-
Sep 21, 2026, 00:27Nicole De Vita: The Global Burden of Iron Deficiency and Anemia in Women at SABM